Alaunos Therapeutics Inc Cash Flow Conversion Efficiency
Alaunos Therapeutics Inc cash flow conversion efficiency. Based on the latest financial reports, Alaunos Therapeutics Inc (TCRT) has a cash flow conversion efficiency ratio of -0.460x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-300.00K) by net assets ($652.00K). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Alaunos Therapeutics Inc (2001–2025)
Cash flow conversion efficiency of Alaunos Therapeutics Inc from 2001 to 2025. This chart illustrates how Alaunos Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View latest Alaunos Therapeutics Inc stock price today for real-time trading data and today's change.
Alaunos Therapeutics Inc Cash Flow Conversion Ratio Explained
Alaunos Therapeutics Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Alaunos Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Alaunos Therapeutics Inc ranked by their cash flow conversion efficiency. Also see market cap of Alaunos Therapeutics Inc for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Global Health Ltd
AU:GLH
|
0.017x |
|
Jost AG
MU:JOX
|
N/A |
|
Easson Holdings Ltd
PA:MLEAS
|
N/A |
|
paragon GmbH & Co. KGaA
F:PGN
|
0.013x |
|
Galeo Concept SA
PA:MLGAL
|
N/A |
|
TECH INVEST GROUP ZY-02
F:6N2
|
0.044x |
|
Nobel29 Resources Corp
V:NBLC
|
0.055x |
|
Yowie Group Ltd
AU:YOW
|
-0.091x |
Annual Cash Flow Conversion Efficiency for Alaunos Therapeutics Inc (2001–2025)
The table below shows the annual cash flow conversion efficiency of Alaunos Therapeutics Inc from 2001 to 2025. Review how much free cash does Alaunos Therapeutics Inc generate to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $2.15 Million | $-2.87 Million | -1.333x | +44.70% |
| 2024-12-31 | $2.06 Million | $-4.97 Million | -2.410x | +49.58% |
| 2023-12-31 | $6.31 Million | $-30.14 Million | -4.779x | -530.33% |
| 2022-12-31 | $38.55 Million | $-29.23 Million | -0.758x | +28.39% |
| 2021-12-31 | $58.06 Million | $-61.47 Million | -1.059x | -130.24% |
| 2020-12-31 | $123.98 Million | $-57.01 Million | -0.460x | -6.94% |
| 2019-12-31 | $95.01 Million | $-40.85 Million | -0.430x | +25.61% |
| 2018-12-31 | $85.56 Million | $-49.46 Million | -0.578x | -202.35% |
| 2017-12-31 | $-96.81 Million | $-54.67 Million | 0.565x | -25.16% |
| 2016-12-31 | $-77.30 Million | $-58.33 Million | 0.755x | +659355.55% |
| 2015-12-31 | $87.37 Million | $-10.00K | 0.000x | +99.99% |
| 2014-12-31 | $33.84 Million | $-36.65 Million | -1.083x | +10.13% |
| 2013-12-31 | $49.38 Million | $-59.51 Million | -1.205x | +25.95% |
| 2012-12-31 | $48.45 Million | $-78.83 Million | -1.627x | -200.04% |
| 2011-12-31 | $71.61 Million | $-38.84 Million | -0.542x | +15.86% |
| 2010-12-31 | $30.55 Million | $-19.69 Million | -0.645x | -47.35% |
| 2009-12-31 | $28.10 Million | $-12.29 Million | -0.437x | +87.47% |
| 2008-12-31 | $6.74 Million | $-23.52 Million | -3.490x | -389.56% |
| 2007-12-31 | $30.37 Million | $-21.65 Million | -0.713x | -31.16% |
| 2006-12-31 | $26.53 Million | $-14.42 Million | -0.544x | +55.42% |
| 2005-12-31 | $7.20 Million | $-8.78 Million | -1.219x | -450.55% |
| 2004-12-31 | $-21.02K | $-7.31K | 0.348x | -4.28% |
| 2003-12-31 | $-25.69K | $-9.33K | 0.363x | -46.49% |
| 2002-12-31 | $-17.33K | $-11.77K | 0.679x | -94.13% |
| 2001-12-31 | $-2.62K | $-30.26K | 11.570x | -- |
About Alaunos Therapeutics Inc
Alaunos Therapeutics, Inc., a pre-clinical stage biopharmaceutical company that develops orally administered small-molecule therapeutics for the treatment of obesity and related metabolic disorders. It develops non-hormonal, non-incretin approach, and unlike hormone-based treatments, such as GLP-1 drugs. The company also develops hunTR TCR discovery platform to target driver mutations. Alaunos Th… Read more